Informations générales (source: ClinicalTrials.gov)
A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).
Interventional
Phase 1/Phase 2
Celgene (Voir sur ClinicalTrials)
mai 2019
février 2028
25 juillet 2025
The purpose of this study is to evaluate the safety, tolerability, and preliminary
efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants
with relapsed or refractory non-Hodgkin's lymphomas.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Vincent RIBRAG | 17/05/2024 13:48:09 | Contacter | ||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Local Institution - 401 - 94805 - Villejuif CEDEX - France | Contact (sur clinicalTrials) | ||||
| Local Institution - 402 - 69495 - Pierre-Benite CEDEX - France | Contact (sur clinicalTrials) | ||||
| Local Institution - 403 - 94010 - Creteil - France | Contact (sur clinicalTrials) | ||||
| Local Institution - 404 - 76038 - Rouen - France | Contact (sur clinicalTrials) | ||||
| Local Institution - 405 - 75010 - Paris - France | Contact (sur clinicalTrials) | ||||
| Local Institution - 406 - 59037 - Lille - France | Contact (sur clinicalTrials) | ||||
| Local Institution - 407 - 33076 - Bordeaux - France | Contact (sur clinicalTrials) | ||||
| Local Institution - 408 - 31200 - Toulouse - France | Contact (sur clinicalTrials) | ||||
| Local Institution - 409 - 34295 - Montpellier - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- History of Non-Hodgkin's Lymphoma (NHL) with relapsed or refractory disease
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- History of Non-Hodgkin's Lymphoma (NHL) with relapsed or refractory disease
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- Life expectancy ≤ 2 months
- Received prior systemic anti-cancer treatment (approved or investigational) ≤ 5
half-lives or 4 weeks prior to starting CC-99282, whichever is shorter
- Is on chronic systemic immunosuppressive therapy or corticosteroids or has
clinically significant graft-versus-host disease (GVHD)
- Impaired cardiac function or clinically significant cardiac disease
Other protocol-defined inclusion/exclusion criteria apply